KR102421006B1 - 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도 - Google Patents

두통의 예방학적 치료를 위한 카바메이트 화합물의 용도 Download PDF

Info

Publication number
KR102421006B1
KR102421006B1 KR1020170060706A KR20170060706A KR102421006B1 KR 102421006 B1 KR102421006 B1 KR 102421006B1 KR 1020170060706 A KR1020170060706 A KR 1020170060706A KR 20170060706 A KR20170060706 A KR 20170060706A KR 102421006 B1 KR102421006 B1 KR 102421006B1
Authority
KR
South Korea
Prior art keywords
formula
headache
migraine
pharmaceutical composition
carbamate compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020170060706A
Other languages
English (en)
Korean (ko)
Other versions
KR20170131240A (ko
Inventor
신혜원
박윤경
Original Assignee
에스케이바이오팜 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스케이바이오팜 주식회사 filed Critical 에스케이바이오팜 주식회사
Publication of KR20170131240A publication Critical patent/KR20170131240A/ko
Application granted granted Critical
Publication of KR102421006B1 publication Critical patent/KR102421006B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020170060706A 2016-05-19 2017-05-16 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도 Active KR102421006B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160061374 2016-05-19
KR1020160061374 2016-05-19

Publications (2)

Publication Number Publication Date
KR20170131240A KR20170131240A (ko) 2017-11-29
KR102421006B1 true KR102421006B1 (ko) 2022-07-14

Family

ID=60325338

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020170060706A Active KR102421006B1 (ko) 2016-05-19 2017-05-16 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도

Country Status (8)

Country Link
US (2) US10456376B2 (OSRAM)
EP (1) EP3459541B1 (OSRAM)
JP (1) JP6986521B2 (OSRAM)
KR (1) KR102421006B1 (OSRAM)
CN (1) CN109310670B (OSRAM)
CA (1) CA3024278A1 (OSRAM)
ES (1) ES2893456T3 (OSRAM)
WO (1) WO2017200316A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11406620B2 (en) * 2017-11-14 2022-08-09 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing or treating diseases associated with increase in late sodium current
ES2978226T3 (es) * 2018-09-21 2024-09-09 Sk Biopharmaceuticals Co Ltd Compuesto de carbamato y uso de la formulación que lo comprende para prevenir, aliviar o tratar el trastorno de estrés agudo o el trastorno de estrés postraumático
CA3113052A1 (en) * 2018-09-21 2020-03-26 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for prevention, alleviation, or treatment of status epilepticus
IL293096A (en) * 2019-11-22 2022-07-01 Sk Biopharmaceuticals Co Ltd Oral pharmaceutical composition comprising carbamate compound and preparation method therefor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100323410A1 (en) 2009-06-22 2010-12-23 Sang Chul Lim Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US20110111467A1 (en) 2009-10-15 2011-05-12 Sang Chul Lim Method for Preparation of Carbamic Acid (R)-1-Aryl-2-Tetrazolyl-Ethyl Ester
KR101286499B1 (ko) * 2005-04-22 2013-07-16 에스케이바이오팜 주식회사 신경치료용 아졸 화합물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
DE2628420A1 (de) * 1976-06-24 1978-01-05 Bayer Ag 1-acyloxy-2-imidazolyl-1-phenyl- aethane, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide und nematizide
US4349556A (en) * 1976-06-24 1982-09-14 Bayer Aktiengesellschaft Pesticidally active 1-acyloxy-1-phenyl-2-azolyl-ethanes
NZ533592A (en) * 2001-12-21 2006-05-26 Ortho Mcneil Pharm Inc Process for preparing 2-(substituted phenyl) - 2 - hydroxy-ethyl carbamates
DE602005020667D1 (de) * 2004-09-16 2010-05-27 Janssen Pharmaceutica Nv Verwendung von 2-phenyl-1,2-ethanediol-(di)carbamaten zur behandlung von epileptogenese
CN102574344B (zh) 2009-10-16 2016-03-02 诺华股份有限公司 用于运输接触透镜通过浸浴的设备及方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101286499B1 (ko) * 2005-04-22 2013-07-16 에스케이바이오팜 주식회사 신경치료용 아졸 화합물
US20100323410A1 (en) 2009-06-22 2010-12-23 Sang Chul Lim Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US20110111467A1 (en) 2009-10-15 2011-05-12 Sang Chul Lim Method for Preparation of Carbamic Acid (R)-1-Aryl-2-Tetrazolyl-Ethyl Ester

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Epilepsy Research, 92(2-3):89-124 (2010.12.01.)
European Journal of Medicinal Chemistry, 36(5):421-433 (2001)
NEUROLOGIC ASPECTS OF SYSTEMIC DISEASE PART I: "Chapter 33: Fibromyalgia", HANDBOOK OF CLINICAL NEUROLOGY, 119:513-527 (2014)
Novel Neurotherapeutic for Epilepsy, Neuropathic Pain and Bipolar Disorder, YKP3089 - SK biopharmaceuticals, <https://www.epilepsy.com/sites/core/files/atoms/files/6-6_S_James_Lee.pdf>(2012.12.31.)

Also Published As

Publication number Publication date
JP2019516726A (ja) 2019-06-20
US10456376B2 (en) 2019-10-29
EP3459541B1 (en) 2021-09-15
KR20170131240A (ko) 2017-11-29
ES2893456T3 (es) 2022-02-09
JP6986521B2 (ja) 2021-12-22
CN109310670B (zh) 2022-03-29
US20190216780A1 (en) 2019-07-18
CA3024278A1 (en) 2017-11-23
CN109310670A (zh) 2019-02-05
EP3459541A1 (en) 2019-03-27
WO2017200316A1 (ko) 2017-11-23
US20200009113A1 (en) 2020-01-09
EP3459541A4 (en) 2020-01-08

Similar Documents

Publication Publication Date Title
KR102421006B1 (ko) 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도
JP7071287B2 (ja) 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用
US11571410B2 (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
RU2751504C2 (ru) Применение карбамата для предупреждения или лечения невралгии тройничного нерва
JP7417595B2 (ja) てんかん重積状態の予防、軽減又は治療のためのカルバメート化合物の使用
IL274431B1 (en) Use of a carbamate compound to reduce or treat developmental disorders including fragile X syndrome, Engelmann syndrome, or Rett syndrome
EP3854391B1 (en) Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
EP3556363B1 (en) Use of carbamate compound for prevention, alleviation or treatment of pruritus
HK40003858B (en) Use of carbamate compound in order to preventatively treat headaches
HK40003858A (en) Use of carbamate compound in order to preventatively treat headaches
RU2774970C2 (ru) Применение карбаматных соединений для профилактики, облегчения или лечения биполярного расстройства
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
HK40005640B (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20170516

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200515

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 20170516

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220314

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220704

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220711

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220711

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250610

Start annual number: 4

End annual number: 4